Biopharma CEOs plot path to countering COVID-19 at White House meeting; Regeneron could make 200,000 doses/month by August

At a White House meeting Monday, biopharmaceutical executives presented a road map for a phased deployment of drugs and vaccines to combat COVID-19.

There was some misunderstanding around the table about the differences between vaccines and mAbs, and about the distinctions between starting a clinical trial, mass-producing a product, and receiving regulatory approval. ...